Neurology Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
12:39
Jan 12
Jan 12
Patent cliffs drive big pharma biotech M&A.
Large pharmaceutical companies facing patent cliffs will look to fill lost top-line revenue by acquiring smaller biotech companies with mid-stage, late-stage, or commercial-stage drugs. We've seen large pharma anticipate this, and the areas of high unmet need where they seek innovation are oncology, inflammatory and immune diseases, and neurology. This should drive continued biotech M&A.
HIGH
About Neurology Investor Commentary
Across the available history and selected sources, Buzzberg tracks Neurology across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Graig Suvannavejh.